- Home
- STHO vs CNTB Comparison
STHO vs CNTB Comparison
Compare STHO & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STHO | CNTB |
|---|---|---|
| Founded | 2022 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 118.3M | 140.4M |
| IPO Year | 2022 | 2020 |
Fundamental Metrics
Financial Performance| Metric | STHO | CNTB |
|---|---|---|
| Price | $9.83 | $2.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | 17.1K | ★ 513.0K |
| Earning Date | 05-08-2026 | 08-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 24.73 | N/A |
| EPS | ★ 2.58 | N/A |
| Revenue | ★ $110,143,000.00 | $64,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.73 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.08 | $1.23 |
| 52 Week High | $9.94 | $3.82 |
Technical Indicators
Market Signals| Indicator | STHO | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 51.81 | 58.62 |
| Support Level | $8.71 | $2.30 |
| Resistance Level | $9.76 | $2.69 |
| Average True Range (ATR) | 0.28 | 0.18 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 66.31 | 76.60 |
Price Performance
Historical ComparisonAbout STHO Star Holdings Shares of Beneficial Interest
Star Holdings engages in non-ground lease-related businesses, including real estate finance, operating properties, and land and development. Its portfolio is comprised of its interests in Asbury and Magnolia Green residential development projects, a portfolio of commercial real estate properties, and loans that are being marketed for sale. The Company operates its business through one reportable and operating segment that focuses on realizing value for shareholders by generating cash flows through active asset management and sales of its existing loans, operating properties, and land and development properties.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.